Content Type: Commentary & Opinion

CAAP Rule and Prescription Drug Prices

March 15, 2026

Mitigating Bias in Machine Learning for Medicine

March 15, 2026

How Should Clinicians and Organizations Assess Risks and Benefits of First-In-Human Implantation of Investigational Devices?

March 15, 2026

Safety, Supply, and Suits—Litigation and the Vaccine Industry

March 15, 2026

Who Owns Federally Funded Research? The Supreme Court and the Bayh-Dole Act

March 15, 2026

The NIH Translational Research Center Might Trade Public Risk for Private Reward

March 15, 2026

Ethical Considerations in Orphan Drug Approval and Use

March 15, 2026

Think Globally, Prescribe Locally: How Rational Pharmaceutical Policy in the U.S. Can Improve Global Access to Essential Medicines

March 15, 2026

Drug Development for Neglected Diseases—The Trouble with FDA Review Vouchers

March 15, 2026

Managing Financial and Nonfinancial Conflicts of Interest in Healthcare Delivery

March 15, 2026

Where Cost, Medical Necessity, and Morality Meet: Should US Government Insurance Programs Pay for Erectile Dysfunction Drugs?

March 15, 2026

The Strength and Importance of Government-Funded Patents for Approved Drugs (Reply)

March 6, 2026